TY - JOUR
T1 - Biologic therapy in idiopathic inflammatory myopathy
AU - Selva-O'Callaghan, Albert
AU - Ramos Casals, Manel
AU - Grau Junyent, Josep M.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - The aim of this article is to study the evidence-based knowledge related to the use of biological therapies in patients diagnosed with idiopathic inflammatory myopathy (dermatomyositis, polymyositis and inclusion body myositis). In this review the leading published studies related to the use of biological therapy in patients with myositis are analysed; mainly those with high methodological standards, that means randomized and controlled studies. Methodological drawbacks due to the rarity and heterogeneity of these complex diseases are also addressed. Up to now is not possible to ascertain the biologics as a recommended therapy in patients with myositis, at least based in the current evidence-based knowledge, although it can not be neglected as a therapeutic option in some clinical situations, taking into account the scarce of effective treatments in those patients, especially in refractory myositis. Future studies probably will help to better define the role of biological therapies in patients with idiopathic inflammatory myopathy. © 2013 Elsevier Espan a, S.L.U. All rights reserved.
AB - The aim of this article is to study the evidence-based knowledge related to the use of biological therapies in patients diagnosed with idiopathic inflammatory myopathy (dermatomyositis, polymyositis and inclusion body myositis). In this review the leading published studies related to the use of biological therapy in patients with myositis are analysed; mainly those with high methodological standards, that means randomized and controlled studies. Methodological drawbacks due to the rarity and heterogeneity of these complex diseases are also addressed. Up to now is not possible to ascertain the biologics as a recommended therapy in patients with myositis, at least based in the current evidence-based knowledge, although it can not be neglected as a therapeutic option in some clinical situations, taking into account the scarce of effective treatments in those patients, especially in refractory myositis. Future studies probably will help to better define the role of biological therapies in patients with idiopathic inflammatory myopathy. © 2013 Elsevier Espan a, S.L.U. All rights reserved.
KW - Biologic therapy
KW - Idiopathic inflammatory myopathy
KW - Myositis
U2 - 10.1016/j.medcli.2013.11.009
DO - 10.1016/j.medcli.2013.11.009
M3 - Review article
SN - 0025-7753
VL - 143
SP - 275
EP - 280
JO - Medicina Clinica
JF - Medicina Clinica
IS - 6
ER -